EUVIMEDEUVIMED entdecken
Crossref

Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa

Xuehan Sun iD, Chen Liang, Yangcan Chen, Tongtong Cui, Jiabao Han, Moyu Dai, Ying Zhang, Qi Zhou, Wei Li

Human Gene Therapy · 2024

DOI: 10.1089/hum.2023.201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Xuehan Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Hauptthemen laut MEDLINE: Retinitis Pigmentosa, Retinal Degeneration. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the rhodopsin (RHO) gene are the predominant causes of autosomal dominant retinitis pigmentosa (adRP). Given the diverse gain-of-function mutations, therapeutic strategies targeting specific sequences face significant challenges. Here, we provide a universal approach to conquer this problem: we have devised a CRISPR-Cas12i-based, mutation-independent gene knockout and replacement compound therapy carried by a dual AAV2/8 system. In this study, we successfully delayed the progression of retinal degeneration in the classic mouse disease model RhoP23H, and also RhoP347S, a new native mouse mutation model we developed. Our research expands the horizon of potential options for future treatments of RHO-mediated adRP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinitis PigmentosaRetinal DegenerationMiceAnimalsRhodopsinMice, KnockoutMutationGenes, Dominant

Stichwörter der Autor:innen

adeno-associated viral vectorsautosomal dominant retinitis pigmentosagene editinggene therapyrhodopsin

Substanzen

Rhodopsin

Autor:innen und Institutionen

  • State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
  • Key Laboratory of Organ Regeneration and Reconstruction, Chinese Academy of Sciences, Beijing, China.
  • University of Chinese Academy of Sciences, Beijing, China; and.
  • Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.

ORCID-Profile: Xuehan Sun

Zitieren

APA

Sun, X., Liang, C., Chen, Y., Cui, T., Han, J., Dai, M., Zhang, Y., Zhou, Q., & Li, W. (2024). Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy. https://doi.org/10.1089/hum.2023.201

Vancouver

Sun X, Liang C, Chen Y, Cui T, Han J, Dai M, et al. Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy. 2024. doi:10.1089/hum.2023.201

BibTeX
@article{Sun2024,
  author = {Sun, Xuehan and Liang, Chen and Chen, Yangcan and Cui, Tongtong and Han, Jiabao and Dai, Moyu and Zhang, Ying and Zhou, Qi and Li, Wei},
  title = {Knockout and Replacement Gene Surgery to Treat Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa},
  journal = {Human Gene Therapy},
  year = {2024},
  doi = {10.1089/hum.2023.201}
}
Kostenlos starten →